These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 6956429)

  • 1. Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and non-Hodgkin's lymphoma.
    Ettinger LJ; Chervinsky DS; Freeman AI; Creaven PJ
    Cancer; 1982 Nov; 50(9):1676-82. PubMed ID: 6956429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis.
    Tetef ML; Margolin KA; Doroshow JH; Akman S; Leong LA; Morgan RJ; Raschko JW; Slatkin N; Somlo G; Longmate JA; Carroll MI; Newman EM
    Cancer Chemother Pharmacol; 2000; 46(1):19-26. PubMed ID: 10912573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma.
    Pitman SW; Frei E
    Cancer Treat Rep; 1977 Jul; 61(4):695-701. PubMed ID: 18282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose methotrexate as part of remission maintenance therapy for childhood acute lymphocytic leukemia: a Pediatric Oncology Group pilot study.
    Frankel LS; Wang YM; Shuster J; Nitschke R; Doering EJ; Pullen J
    J Clin Oncol; 1983 Dec; 1(12):804-9. PubMed ID: 6583318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose methotrexate in acute lymphocytic leukemia.
    Freeman AI; Wang JJ; Sinks LF
    Cancer Treat Rep; 1977 Jul; 61(4):727-31. PubMed ID: 267510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacokinetics of intrathecal chemotherapy and clinical problems].
    Fujimoto T
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1536-42. PubMed ID: 6433796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid drug levels of leukemic children receiving intravenous 5 g/m2 methotrexate.
    Millot F; Rubie H; Mazingue F; Mechinaud F; Thyss A
    Leuk Lymphoma; 1994 Jun; 14(1-2):141-4. PubMed ID: 7920221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disposition of intermediate-dose methotrexate in children with acute lymphocytic leukemia.
    Evans WE; Stewart CF; Hutson PR; Cairnes DA; Bowman WP; Yee GC; Crom WR
    Drug Intell Clin Pharm; 1982 Nov; 16(11):839-42. PubMed ID: 6959800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum and cerebrospinal fluid distribution of 5-methyltetrahydrofolate after intravenous calcium leucovorin and intra-Ommaya methotrexate administration in patients with meningeal carcinomatosis.
    Mehta BM; Glass JP; Shapiro WR
    Cancer Res; 1983 Jan; 43(1):435-8. PubMed ID: 6600162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion.
    Evans WE; Hutson PR; Stewart CF; Cairnes DA; Bowman WP; Rivera G; Crom WR
    Clin Pharmacol Ther; 1983 Mar; 33(3):301-7. PubMed ID: 6600662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic high-dose ara-C for the treatment of meningeal leukemia in adult acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
    Morra E; Lazzarino M; Inverardi D; Brusamolino E; Orlandi E; Canevari A; Pagnucco G; Bernasconi C
    J Clin Oncol; 1986 Aug; 4(8):1207-11. PubMed ID: 3461134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remission induction of meningeal leukemia with high-dose intravenous methotrexate.
    Balis FM; Savitch JL; Bleyer WA; Reaman GH; Poplack DG
    J Clin Oncol; 1985 Apr; 3(4):485-9. PubMed ID: 3856631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid and plasma methotrexate levels following high-dose regimen given as a 3-hour intravenous infusion in children with nonHodgkin's lymphoma.
    Vassal G; Valteau D; Bonnay M; Patte C; Aubier F; Lemerle J
    Pediatr Hematol Oncol; 1990; 7(1):71-7. PubMed ID: 2397170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?
    Niemann A; Mühlisch J; Frühwald MC; Gerss J; Hempel G; Boos J
    Ther Drug Monit; 2010 Aug; 32(4):467-75. PubMed ID: 20571463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variability in the disposition of intraventricular methotrexate: a proposal for rational dosing.
    Strother DR; Glynn-Barnhart A; Kovnar E; Gregory RE; Murphy SB
    J Clin Oncol; 1989 Nov; 7(11):1741-7. PubMed ID: 2809687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
    Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
    Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study on the pharmacokinetics of 7-hydroxy-methotrexate after administration of methotrexate in the dose range of 0.5-33.6 g/m2 to children with acute lymphoblastic leukemia.
    Borsi JD; Sagen E; Romslo I; Moe PJ
    Med Pediatr Oncol; 1990; 18(3):217-24. PubMed ID: 2329967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia.
    Borsi JD; Moe PJ
    Cancer; 1987 Jul; 60(1):5-13. PubMed ID: 3472638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients].
    Lin XB; Zhou NN; Li S; Cai QQ; Xia ZJ; Liao H; Gao Y; Huang HQ
    Ai Zheng; 2008 Oct; 27(10):1100-5. PubMed ID: 18851792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.
    Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B
    J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.